Information  X 
Enter a valid email address

RUA Life Sciences (RUA)

  Print      Mail a friend

Wednesday 30 December, 2020

RUA Life Sciences

Results of GM, TVR and Directors' Dealings

RNS Number : 1594K
RUA Life Sciences PLC
30 December 2020
 

30 December 2020

 

RUA Life Sciences plc

(the "Company" or the "Group")

 

Results of General Meeting

Total Voting Rights

Director/PDMR Dealings

 

 

RUA Life Sciences plc (AIM: RUA), the holding company of a group of medical device businesses focused on the exploitation of Elast-Eon™, a long-term implantable biostable polymer, is pleased to announce that at the General Meeting held earlier today, all resolutions proposed were duly passed by shareholders. 

 

Furthermore, as announced earlier today the Open Offer closed for acceptances at 11.00 a.m. on 29 December 2020 with final valid applications from Qualifying Shareholders in respect of 831,522 Open Offer Shares. Qualifying Shareholders who have validly applied for Open Offer Shares have received their full Open Offer Entitlement.  Applications made under the Excess Application Facility were oversubscribed and have been scaled back pro-rata such that approximately 9.7 per cent. of the Excess Application is satisfied.

 

Accordingly, the Company will raise a total of approximately £7.0 million (before expenses) through the Placing, Subscription and Open Offer and has thus issued and allotted 5,831,522 New Ordinary Shares. An application has been made for the 5,831,522 New Ordinary Shares to be admitted to trading on AIM, which is expected to take place at 8.00 a.m. on 31 December 2020.

 

The net proceeds of the Placing, Subscription and Open Offer will be used by the Company primarily to fund the acceleration of the Group's surgical heart valve through to human trials, to accelerate development of the Company's TAVI valve, to scale up the Group's graft manufacture to meet anticipated demand and to allow further investment in capital equipment to assist in the scale up of the Group's capacity.

 

Following Admission, the Company's issued share capital will comprise 22,184,797 Ordinary Shares, of which none are held in treasury, and 4,832,778 Deferred Shares which carry no voting rights. The above figure of 22,184,797 may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the voting rights of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Details of the proxy votes received on each resolution by the Company's Registrar are set out below:

 

 

Resolution

For &
Discretionary

Against

Withheld

Total votes cast

 

 

Number of votes

%

Number of votes

%

Number of votes

%

 

1

Allotment of Ordinary Shares for Fundraising

3,587,593

99.19

28,968

0.80

328

0.01

3,616,889

2

Pre-emption rights Fundraising

3,587,593

99.19

28,968

0.80

328

0.01

3,616,889

3

Allotment of Ordinary Shares, general authority

3,587,593

99.19

28,968

0.80

328

0.01

3,616,889

4

Pre-emption rights

3,586,593

99.16

28,968

0.80

1,328

0.04

3,616,889

5

Pre-emption rights, acquisitions and specified investments

3,586,593

99.16

28,968

0.80

1,328

0.04

3,616,889

 

John Ely, a Non-Executive Director of the Company and Anthea Berg, a Person Closely Associated with Geoffrey Berg, a Non-Executive Director of the Company, have subscribed for New Ordinary Shares through the Subscription as detailed below.

Director/PDMR

Shares Acquired

Total Holding*

Percentage of Enlarged Share Capital*

John Ely

4,167

4,167

0.0%

Geoffrey Berg**

8,333

25,018

0.1%

* following Admission

** Application made in the name of Anthea Berg, wife of Geoffrey Berg

 

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the circular sent to Shareholders on 11 December 2020.

 

 

For more information please contact:

 

 

 

RUA Life Sciences plc

 

Bill Brown, Chairman

David Richmond, CEO

 

Tel: +44 (0) 77 3071 8296

Tel: +44 (0) 78 9999 6400

Shore Capital (Nomad and Joint Broker)

Tom Griffiths/David Coaten

 

Cenkos Securities plc (Joint Broker)

Russell Cook/Max Gould (Corporate Finance)

Michael Johnson (Sales)

 

Tel: +44 (0)20 7408 4080

 

 

Tel: +44 (0) 20 7397 8900

 

 

 

About RUA Life Sciences plc

 

The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.

 

Our vision is to improve the lives of millions of patients by improving and enabling medical devices with Elast-Eon™, widely accepted as being the most biostable of all long-term implantable polyurethanes.

 

Whether it is licensing Elast-Eon™, manufacturing a device or component or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.

 

Elast-Eon™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 7 million implants and over 14 years of successful clinical use, the Group's polymers are proven in long-term life enabling applications.

 

The Group's four business units are:

 

RUA Medical :

End-to-end contract developer and manufacturer of medical devices and implantable fabric specialist.

RUA Biomaterials :

Licensor of Elast-EonTM polymers to the medical device industry.

RUA Vascular :

Commercialisation of large bore polymer sealed grafts and soft tissue patches.

RUA Structural Heart :

Development of tri leaflet polymeric heart valves.

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

John Ely

2

Reason for notification

Acquisition of shares

a.

Position/Status

Non-Executive Director

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

RUA Life Sciences Plc

b.

LEI

213800BMVB22PVOJ9Z28 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of 5p each

 

 

ISIN: GB0033360586

 

b.

Nature of the transaction

Share purchase

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s) per share

Volume(s)

 

120p

4,167

 

 

 

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

n/a

 

 

 

e.

Date of the transaction

31 December 2020

f.

Place of the transaction

London Stock Exchange

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Anthea Berg, PCA with Geoffrey Berg

2

Reason for notification

Acquisition of shares

a.

Position/Status

Wife of Non-Executive Director

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

RUA Life Sciences Plc

b.

LEI

213800BMVB22PVOJ9Z28 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of 1p each

 

 

ISIN: GB0033360586

 

b.

Nature of the transaction

Share purchase

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s) per share

Volume(s)

 

120p

8,333

 

 

 

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

n/a

 

 

 

e.

Date of the transaction

31 December 2020

f.

Place of the transaction

London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMEAFAEDDLEFFA

a d v e r t i s e m e n t